Korea’s SK Biopharma eyes 2019 listing
South Korean company SK Biopharmaceuticals is planning to launch an IPO by the end of 2019 and could net proceeds of up to around W1tr ($838.5m), according to a source close to the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts